Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 study

已完结 10 由 hoho 发布于 2026/7/23 14:39:02

DOI:10.1016/s1470-2045(25)00376-6
作者：Guoming Shi, Xiaoyong Huang, Xiaowu Li, Fei Liang, Qiang Gao, Daohan Zhang, Jiacheng Lu, Yuan Ji, Zhiqiang Hu, Yi Chen, Shuangjian Qiu, Yong Yi, Xiaodong Zhu, Huichuan Sun, Yinghong Shi, MinJie Peng,
文献类型：期刊论文
补充材料：只需要正文

Elsevier

Abstract：BackgroundThe optimal conversion regimen that allows more patients with unresectable biliary tract cancer to access surgery remains unclear; there is currently no standard conversion therapy

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:NatureRNA chemistry and therapeutics